Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.47 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.40 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | AHR | P35869 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 4/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 3/20 | 0.36 |
| ▸ | ACLY | P53396 | 2/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68990 | 0.81 | TRPV4 (0.58) | AKR1B1PFKFB3TRPV4EPHX2KMT2A | |
| SCHEMBL27619523 | 0.81 | AKR1B1 (0.49) | AKR1B1PFKFB3TRPV4EPHX2KMT2A | |
| SCHEMBL29651884 | 0.81 | TRPV4 (0.58) | AKR1B1PFKFB3TRPV4EPHX2KMT2A | |
| SCHEMBL1942774 | 0.79 | CA1 (0.48) | AKR1B1 | |
| SCHEMBL30860761 | 0.79 | AKR1B1 (0.47) | AKR1B1PFKFB3TRPV4EPHX2KMT2A | |
| SCHEMBL2050647 | 0.79 | AKR1B1 (0.47) | AKR1B1PFKFB3TRPV4EPHX2KMT2A | |
| SCHEMBL644001 | 0.79 | CCR2 (0.50) | AKR1B1TRPV4BRD4CNR2CCR2 | |
| SCHEMBL3268704 | 0.78 | AKR1B1 (0.45) | AKR1B1TRPV4KMT2AMCL1 | |
| SCHEMBL1638742 | 0.78 | AKR1B1 (0.46) | AKR1B1AHRCCR2 | |
| Hydrochloric Acid SCHEMBL27591579 | 0.78 | AKR1B1 (0.46) | AKR1B1PFKFB3TRPV4EPHX2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111646973-B | Polysubstituted quinazoline derivative and preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2022-07-19 | — | — | CN | claimed |
| CN-111646973-A | Polysubstituted quinazoline derivative and preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2020-09-11 | — | — | CN | claimed |
| CN-111646973-A | Polysubstituted quinazoline derivative and preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2020-09-11 | — | — | CN | disclosed |
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1541563-A1 | CCR4 ANTAGONIST AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | CCR4, CCR1, CCR9 | AKR1B1 1462/4885PFKFB3 3136/4885TRPV4 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.